ANDRE DONG WON LEE

(Fonte: Lattes)
Índice h a partir de 2011
5
Projetos de Pesquisa
Unidades Organizacionais
Instituto Central, Hospital das Clínicas, Faculdade de Medicina - Médico

Resultados de Busca

Agora exibindo 1 - 10 de 64
  • article 3 Citação(ões) na Scopus
    Home Parenteral Nutrition Program and Referral of Potential Candidates for Intestinal and Multivisceral Transplantation in a Single Brazilian Center
    (2014) LEE, A. D. W.; GALVAO, F. H. F.; DIAS, M. C. G.; CRUZ, M. E.; MARIN, M.; PEDROL, C. N.; DAVID, A. I.; PECORA, R. A. A.; WAITZBERG, D. L.; D'ALBUQUERQUE, L. A. C.
    Intestinal failure is a multifaceted condition that may require high-complexity treatment and a multidisciplinary program, including home parenteral nutrition therapy (HPNT) and intestinal transplantation. In this article, we profile a Brazilian single-center experience with 128 cases of HTPN followed for the last 30 years and appraise the referral for potential intestinal and multivisceral transplantation.
  • article 4 Citação(ões) na Scopus
    Transplante de intestino delgado
    (2013) PÉCORA, Rafael Antonio Arruda; DAVID, André Ibrahim; LEE, André Dong; GALVÃO, Flávio Henrique; CRUZ-JUNIOR, Ruy Jorge; D'ALBUQUERQUE, Luiz Augusto Carneiro
    BACKGROUND: Small bowel transplantation evolution, because of its complexity, was slower than other solid organs. Several advances have enabled its clinical application. AIM: To review intestinal transplantation evolution and its current status. METHOD: Search in MEDLINE and ScIELO literature. The terms used as descriptors were: intestinal failure, intestinal transplantation, small bowel transplantation, multivisceral transplantation. Were analyzed data on historical evolution, centers experience, indications, types of grafts, selection and organ procurement, postoperative management, complications and results. CONCLUSION: Despite a slower evolution, intestinal transplantation is currently the standard therapy for patients with intestinal failure and life-threatening parenteral nutrition complications. It involves some modalities: small bowel transplantation, liver-intestinal transplantation, multivisceral transplantation and modified multivisceral transplantation. Currently, survival rate is similar to other solid organs. Most of the patients become free of parenteral nutrition.
  • article 6 Citação(ões) na Scopus
    THE EFFECT OF ILEOCECAL VALVE REMOVAL IN A MODEL OF SHORT BOWEL SYNDROME
    (2019) SOLER, Wangles Vasconcellos; LEE, Andre Dong; D'ALBUQUERQUE, Eugenia Machado Carneiro; CAPELOZZI, Vera; ALBUQUERQUE, Luiz Carneiro; CAPELHUCHNICK, Peretz; LANCELOTTI, Carmem Penteado; GALVAO, Flavio Henrique Ferreira
    Background: Short bowel syndrome is a harmful condition that needs experimental research. Aim: To assess the impact of the ileocecal valve removal in a model of short bowel syndrome, in order to investigate the evolution of the colon under this circumstance. Method: Fifteen Wistar rats were equitable divided into: Control (Sham), Group I (70% enterectomy preserving ileocecal valve) and Group II (70% enterectomy excluding ileocecal valve). After enterectomy was performed jejunoileal or jejunocecal anastomosis and sacrificed the animals on 30""' postoperative day for histomorphometric study of the colon. During this period, was observed the clinical evolution of the animals weekly including body weight measurement. Results: Group I and II presented progressive loss of weight. in Group I was observed diarrhea, perinea! hyperemia and purple color of the colon during autopsy. Histomorphometry assay showed hypertrophy and hyperplasia of colon mucosa in Group I. in Group II the colon wall was thicker due to hypertrophy and muscular hyperplasia, and in mucosa vascular proliferation and inflammatory infiltrate were intense. Conclusion: This short bowel syndrome model is relevant and achieve 100% of survival. Animal's weight loss was not altered by the presence or exclusion of the ileocecal valve. Animals with 70% of small bowel removal and presence of the ileocecal valve attained a better clinical evolution and histological colon adaptation than those without ileocecal valve.
  • bookPart
    Complicações da terapia nutricional enteral (TNE)
    (2022) ROCHA, Mariana Hollanda Martins da; LEE, André Dong Won; GOASTICO, Sabrina Segatto Valadares; KOPEL, Liliane; WATANABE, Bianca Mayumi; SEKI, Ana Elisa Boreck; WAITZBERG, Dan Linetzky
  • bookPart
    Fluidoterapia perioperatória
    (2023) FONSECA, Plínio Augusto Moreira; FARIA, William Macedo; LEE, André Dong Won; ROCHA, Mariana Hollanda Martins da
  • conferenceObject
    The Role of the Social Worker Concerning Intestinal Rehabilitation and Transplantation in a Latin American Center
    (2021) GALVAO, F.; LEE, A.; TANJI, J.; RANA, T.; DUARTE, M.; SCABIA, T.; WAISBERG, D.; ROCHA, M.; PINHEIRO, R.; CARNEIRO-D'ALBUQUERQUE, L.
  • conferenceObject
    Adequate Exposure to Tacrolimus with Sublingual Administration
    (2021) MACIEL, A.; FORTUNATO, A.; WAISBERG, D.; GALVAO, F.; LEE, A.; ARANTES, Jr R.; ROCHA, M.; TANIGAWA, R.; DUCATTI, L.; MARTINO, R.; NACIF, L.; ROCHA-SANTOS, V; ANDRAUS, W.; D'ALBUQUERQUE, L.
  • article 27 Citação(ões) na Scopus
    Home parenteral nutrition provision modalities for chronic intestinal failure in adult patients: An international survey
    (2020) PIRONI, Loris; STEIGER, Ezra; BRANDT, Chrisoffer; JOLY, Francisca; WANTEN, Geert; CHAMBRIER, Cecile; AIMASSO, Umberto; SASDELLI, Anna Simona; ZERASCHI, Sarah; KELLY, Darlene; SZCZEPANEK, Kinga; JUKES, Amelia; CARO, Simona Di; THEILLA, Miriam; KUNECKI, Marek; DANIELS, Joanne; SERLIE, Mireille; POULLENOT, Florian; WU, Jian; COOPER, Sheldon C.; RASMUSSEN, Henrik H.; COMPHER, Charlene; SEGUY, David; CRIVELLI, Adriana; PAGANO, Maria C.; HUGHES, Sarah-Jane; GUGLIELMI, Francesco W.; KOZJEK, Nada Rotovnik; SCHNEIDER, Stephane M.; GILLANDERS, Lyn; ELLEGARD, Lars; THIBAULT, Ronan; MATRAS, Przemyslaw; ZMARZLY, Anna; MATYSIAK, Konrad; GOSSUM, Andre Van; FORBES, Alastair; WYER, Nicola; TAUS, Marina; VIRGILI, Nuria M.; O'CALLAGHAN, Margie; CHAPMAN, Brooke; OSLAND, Emma; CUERDA, Cristina; SAHIN, Peter; JONES, Lynn; LEE, Andre Dong Won; MASCONALE, Luisa; ORLANDONI, Paolo; LZBEKI, Ferenc; SPAGGIARI, Corrado; BUENO, Marta; DOITCHINOVA-SIMEONOVA, Maryana; GARDE, Carmen; SERRALDE-ZUNIGA, Aurora E.; OLVEIRA, Gabriel; KRZNARIC, Zeljko; CZAKO, Laszlo; KEKSTAS, Gintautas; SANZ-PARIS, Alejandro; JAUREGUI, Estrella Petrina; MURILLO, Ana Zugasti; SCHAFER, Eszter; ARENDS, Jann; SUAREZ-LLANOS, Jose P.; LAL, Simon
    Background & aims: The safety and effectiveness of a home parenteral nutrition (HPN) program depends both on the expertise and the management approach of the HPN center. We aimed to evaluate both the approaches of different international HPN-centers in their provision of HPN and the types of intravenous supplementation (IVS)-admixtures prescribed to patients with chronic intestinal failure (CIF). Methods: In March 2015, 65 centers from 22 countries enrolled 3239 patients (benign disease 90.1%, malignant disease 9.9%), recording the patient, CIF and HPN characteristics in a structured database. The HPN-provider was categorized as health care system local pharmacy (LP) or independent home care company (HCC). The IVS-admixture was categorized as fluids and electrolytes alone (FE) or parenteral nutrition, either commercially premixed (PA) or customized to the individual patient (CA), alone or plus extra FE (PAFE or CAFE). Doctors of HPN centers were responsible for the IVS prescriptions. Results: HCC (66%) was the most common HPN provider, with no difference noted between benign-CIF and malignant-CIF. LP was the main modality in 11 countries; HCC prevailed in 4 European countries: Israel, USA, South America and Oceania (p < 0.001). IVS-admixture comprised: FE 10%, PA 17%, PAFE 17%, CA 38%, CAFE 18%. PA and PAFE prevailed in malignant-CIF while CA and CAFE use was greater in benign-CIF (p < 0.001). PA + PAFE prevailed in those countries where LP was the main HPN-provider and CA + CAFE prevailed where the main HPN-provider was HCC (p < 0.001). Conclusions: This is the first study to demonstrate that HPN provision and the IVS-admixture differ greatly among countries, among HPN centers and between benign-CIF and cancer-CIF. As both HPN provider and IVS-admixture types may play a role in the safety and effectiveness of HPN therapy, criteria to homogenize HPN programs are needed so that patients can have equal access to optimal CIF care.
  • conferenceObject
    Quality of Life in Patients in Home Parenteral Nutrition in Brazil
    (2021) TANJI, J.; LEE, A.; GALVAO, F.; D'ALBUQUERQUE, L.
  • conferenceObject
    The Role of the Social Worker Concerning Intestinal Rehabilitation and Transplantation in a Latin American Center
    (2021) GALVAO, F.; LEE, A.; TANJI, J.; RANA, T.; DUARTE, M.; SCABIA, T.; WAISBERG, D.; ROCHA, M.; PINHEIRO, R.; CARNEIRO-D'ALBUQUERQUE, L.